International review of neurobiology · 2025
Rescue therapy in myasthenia gravis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bril Vera, Saedi Elham
Аннотация
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating muscle weakness due to impaired neuromuscular transmission. Despite therapeutic advances, acute exacerbations and myasthenic crises remain significant challenges. This chapter offers an in-depth overview of rescue therapies for MG, detailing the mechanisms, efficacy, and safety of established treatments such as IVIG and PLEX, and discussing the potential of novel therapies like eculizumab and efgartigimod in acute MG management. We emphasize the importance of personalized treatment approaches tailored to factors such as antibody status, disease severity, and comorbidities. Strategies for monitoring treatment response and managing complications are also discussed. By synthesizing current evidence and expert recommendations, this chapter aims to equip clinicians with the knowledge needed to optimize rescue therapy in MG, ultimately improving outcomes during acute exacerbations and crises.